A Comparative Study of Continuous Combined Hormone Replacement Therapy and Tibolone on Lipid Metabolism in Postmenopausal Women.
- Author:
Jin Wan PARK
1
;
Eun Ho SONG
;
Won Ki LEE
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Dan Kook University, Cheonan, Korea.
- Publication Type:Comparative Study ; Case Report ; Randomized Controlled Trial
- Keywords:
tibolone;
conjugated equine estrogen;
medroxyprogesterone acetate;
menopause;
lipids
- MeSH:
Body Mass Index;
Cholesterol;
Estrogens;
Female;
Hormone Replacement Therapy*;
Humans;
Lipid Metabolism*;
Medroxyprogesterone Acetate;
Menopause;
Plasma;
Triglycerides
- From:Korean Journal of Obstetrics and Gynecology
2002;45(4):678-681
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To evaluate the effects of tibolone on lipid metabolism in comparison to continuous conjugated equine estrogen and medroxyprogesterone acetate in postmenopausal women METHODS: In a randomized, group-comparative study, the effects on lipid profiles (total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol) were studied between tibolone 2.5 mg/day (N=48) and continuous combined regimen (conjugated equine estrogen 0.625 mg/day combined with medroxyprogesterone acetate 2.5 mg/day, CEE/MPA) (N=46) (CEE/MPA) for 12 month period.Satistical analysis were performed using Student's t-test for paired samples and independent groups. RESULTS: There were no statistical differences in age, age of menopause and body mass index (BMI) of both group before treatment. While treatment with tibolone significantly lowered plasma concentration of triglycerides, there were no significant changes in serum total cholesterol, HDL-cholesterol and LDL-cholesterol levels. In the CEE/MPA group, there were no significant changes of all variables. CONCLUSION: While there a statistically significant decrease in triglyceride concentration in tibolone group. there were no statistically significant differences in total cholesterol, HDL-cholesterol and LDL-cholesterol levels in both tibolone and CEE/MPA group, during 12 months of treatment period.
